Research data ยท Disease model and test

Elevated plus maze in diabetes research

From 2021 to 2025, 70 animal research papers on diabetes mentioned the elevated plus maze in their title or abstract.

That is 5.0 times the 14 papers of 2011 to 2015. Between the same two periods, the papers on diabetes that mention any of the 90 tests we count grew more slowly, to 1.9 times as many.

70 papers on diabetes from 2021 to 2025 mentioned the elevated plus maze
9% of the papers on diabetes that mention any test mention the elevated plus maze
2% of the papers that mention the elevated plus maze are on diabetes
5.0 times as many papers as in 2011 to 2015

Papers by year

Animal research papers on diabetes that mention the elevated plus maze, by year, 2001 to 2026

The 2026 bar counts papers added to PubMed by November 8, 2026.

  • Papers in a full year
  • 2026 so far
Show the counts for each year
Papers by year
YearPapers
20010
20021
20031
20040
20050
20061
20073
20081
20091
20105
20112
20122
20133
20145
20152
20167
20177
20189
201911
202010
202117
202217
202315
20248
202513
2026 (part year)7

Papers on diabetes that mention the elevated plus maze fell from 17 in 2021 to 8 in 2024, then rose to 13 in 2025. Part of this dip may come from PubMed's indexing rather than from fewer studies. Where PubMed has indexed a paper, we take its disease models from that indexing. Otherwise PubTator 3, NCBI's text-mining service, has to find the disease in the title or abstract, or the paper is not counted here. Papers that PubMed indexed under the subject heading Animals also fell and rose, from 200,221 in 2021 to 156,447 in 2023 and 235,479 in 2025.

Which species the papers used

Each bar is a share of the 70 papers from 2021 to 2025. A paper can use more than one species, so the shares can add to more than 100%.

Species

Rat
48 papers 69%
Mouse
22 papers 31%

Tests mentioned alongside the elevated plus maze

Each bar is one test, with how many of the 70 papers also mention it, and what share that is. Of these papers, 9 (13%) mention no other test.

The 12 tests these papers mention most

26 papers 37%
23 papers 33%
16 papers 23%
8 papers 11%
6 papers 9%
5 papers 7%
4 papers 6%

Which papers count

A paper counts here when it is animal research, mentions the elevated plus maze in its title or abstract, and studies diabetes.

We tell whether a paper studies diabetes from its MeSH terms, the subject headings the National Library of Medicine adds when it indexes a paper. For a paper without MeSH terms, PubTator 3, NCBI's text-mining service, has to find the disease in the title or abstract. A paper can count under more than one disease model. A paper that mentions the test only in its methods is missed, so the count runs low.

The page on diabetes research names the subject headings we count as diabetes. Download the test list for the search terms we used for the elevated plus maze, or the paper list for the PubMed ID of every paper behind these counts. Our main page, Behavioral tests in published research, has the full method and each source's terms of use.

More tests and disease models

Every pairing of a disease model and a test with 30 or more papers from 2021 to 2025 has a page like this one.

The page on the elevated plus maze counts all the papers that mention it, whatever they study. The page on diabetes research ranks the tests by their papers on diabetes.

How to cite

APA

ConductScience. (2026, November 10). Elevated plus maze in diabetes research [Data set]. https://conductscience.com/resources/data/behavioral-tests/models/diabetes/elevated-plus-maze

BibTeX

@misc{conductscience_diabetes_elevated_plus_maze_2026,
  author = {{ConductScience}},
  title = {Elevated plus maze in diabetes research},
  year = {2026},
  month = nov,
  url = {https://conductscience.com/resources/data/behavioral-tests/models/diabetes/elevated-plus-maze},
  note = {Data set, released November 10, 2026},
}

Elevated plus maze apparatus in our store

In the test battery tool, pick every test your study will run and add the apparatus for all of them to one quote.